Literature DB >> 6102141

Centrally active N-substituted analogs of 3,4-methylenedioxyphenylisopropylamine (3,4-methylenedioxyamphetamine).

U Braun, A T Shulgin, G Braun.   

Abstract

The known central nervous system activity of 3,4-methylenedioxyphenylisopropylamine and its N-methyl homolog prompted the synthesis of a series of analogs with substituents on the nitrogen atom. Most of these analogs (R = alkyl, alkenyl, hydroxy, alkoxy, and alkoxyalkyl) were prepared by the reductive alkylation of 3,4-methylenedioxyphenylacetone with the appropriate amine and sodium cyanoborohydride. Hindered isomers were synthesized indirectly. Measurements of their pharmacological activity in several animal assays and in human subjects indicated that the central activity decreased with the increasing bulk of the N-substituent.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6102141     DOI: 10.1002/jps.2600690220

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  11 in total

Review 1.  Synthetic cathinones ("bath salts").

Authors:  Matthew L Banks; Travis J Worst; Daniel E Rusyniak; Jon E Sprague
Journal:  J Emerg Med       Date:  2014-02-22       Impact factor: 1.484

Review 2.  Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.

Authors:  Lee E Dunlap; Anne M Andrews; David E Olson
Journal:  ACS Chem Neurosci       Date:  2018-07-12       Impact factor: 4.418

3.  MDMA produces stimulant-like conditioned locomotor activity.

Authors:  L H Gold; G F Koob
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  A role for the mesolimbic dopamine system in the psychostimulant actions of MDMA.

Authors:  L H Gold; C B Hubner; G F Koob
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  In vitro neuronal and vascular responses to 5-HT in rats chronically exposed to MDMA.

Authors:  D M Cannon; A K Keenan; P J Guiry; C Buon; A W Baird; G J McBean
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

6.  Enhancing the anti-lymphoma potential of 3,4-methylenedioxymethamphetamine ('ecstasy') through iterative chemical redesign: mechanisms and pathways to cell death.

Authors:  Agata M Wasik; Michael N Gandy; Matthew McIldowie; Michelle J Holder; Anita Chamba; Anita Challa; Katie D Lewis; Stephen P Young; Dagmar Scheel-Toellner; Martin J Dyer; Nicholas M Barnes; Matthew J Piggott; John Gordon
Journal:  Invest New Drugs       Date:  2011-08-18       Impact factor: 3.850

Review 7.  Role of the serotonin 5-HT(2A) receptor in learning.

Authors:  John A Harvey
Journal:  Learn Mem       Date:  2003 Sep-Oct       Impact factor: 2.460

8.  Synthesis markers in illegally manufactured 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine.

Authors:  M Bohn; G Bohn; G Blaschke
Journal:  Int J Legal Med       Date:  1993       Impact factor: 2.686

9.  Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humans.

Authors:  Matthew J Baggott; Jennifer D Siegrist; Gantt P Galloway; Lynn C Robertson; Jeremy R Coyle; John E Mendelson
Journal:  PLoS One       Date:  2010-12-02       Impact factor: 3.240

10.  Comparative potencies of 3,4-methylenedioxymethamphetamine (MDMA) analogues as inhibitors of [3H]noradrenaline and [3H]5-HT transport in mammalian cell lines.

Authors:  T Montgomery; C Buon; S Eibauer; P J Guiry; A K Keenan; G J McBean
Journal:  Br J Pharmacol       Date:  2007-09-24       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.